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Summary 
Neonatal treatment of rats with Monosodium 
Glutamate (MSG) has been demonstrated to destroy 
cell bodies of neurons in the arcuate nucleus 
including the brain beta-endorphin (B-END) 
system. The effects on opiate receptors of the 
loss of B-END is unknown. Seven to nine month 
old rats treated with MSG on the first two 
postnatal days and lltter matched untreated 
control rats were decapitated and their brains 
dissected into several regions~ Opiate receptor 
assays were carried out ~ith ['H] morphine (mu 
receptor llgand) and [-H] DADL (delta receptor 
ligand) for each brain region for both 
MSG-treated and control rats simultaneously. 
Scatchard plot analyses showed a selective 
increase in delta receptors in the thalamus 
only. No corresponding change in mu receptors 
in the thalamus was found. The cross- 
competition IC5n data supported this conclusion, 
showing a lo~s In the potency of morphine in 
displacing [ H] DADL in the thalamus of MSG 
treated rats. 
Injection of monosodium glutamate (MSG) in neonatal animals 
produces destruction of cell bodies in the arcuate nucleus of 
the hypothalamus (i). Immunocytochemical studies demonstrate a 
loss of the cell bodies and degeneration of the fibers from the 
ACTH/B-END system from arcuate nucleus in brain after MSG 
treatment (2). This destruction of the ACTH/B-END neurons has 
been confirmed by RIA measurements of ACTH and B-END in the 
brain (3). MSG lesions have no clear effect upon pituitary ACTH 
or B-END content (2). 
B-END binds to opiold receptors with good affinity (4). 
The mu and delta subtypes of opiate receptors are most easily 
demonstrated in brain tissue binding studies (5,6). The mu 
receptor preferentially binds morphine, while the delta receptor 
preferentially binds enkephalins and is believed to be the 
receptor for methlonine enkephalin and leuclne enkephalin. 
B-END binds well to both mu and delta receptors in vitro, With a 
slight preference towards the mu receptor. Whether B-END binds 
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to mu or delta receptors or neither in vivo is unclear at this 
point. The destruction from the B-END fibers of the arcuate 
nucleus might be expected to have an effect upon opiate 
receptors in the terminal regions of the brain B-END system. 
Since MSG-treated rats show depletion of brain B-endorphin 
without changes in other endogenous opiates, specific changes in 
opiate binding accompanying this lesion should provide further 
insights into opiate receptor subtype and regulation within this 
system. 
MATERIALS AND METHODS 
Neonatal rats were treated with MSG according to the 
following schedule: 2 grams MSG/kilogram body weight on the 
first two postnatal days; repeat treatment of 4 grams 
MSG/kilogram were done on post natal days 4, 6, and 8 (12). 
Male MSG rats and age and sex matched controls were killed at 
approximately 9 months of age. Female MSG lesioned rats and 
age/sex matched controls were decapitated at approximately 7 
months of age. After decapitation, the brains were rapidly 
removed and dissected on ice into the following brain regions: 
hypothalamus, hippocampus, striatum, frontal cortex, thalamus, 
and mldbraln. Tissue samples from all animals of the same group 
were pooled for homogenization and subsequent opiate receptor 
assays. Some animals were perfused and their brains removed for 
immunohistochemical verification of the destruction of B-END 
cell bodies. 
Opiate receptor binding assays were done on each brain 
region ~f MSG lesioned and control anlmals3simultaneously with 
both I-H] morphine (Amersham) and [ H] D-alanine-2-D- 
leuclne-5-enkephalin (DADL-enkephalin, Amersham). The assays 
were performed using a modification of the opiate receptor 
binding assay of Akil et al (7). Each group contained 7 
animals. The tissues were homogenized in 0.05 M Trls HCI 
buffer, pH 7.4 (at 25°C) with 5% DMSO (dimethylsulfoxide) to 
minimize freezing effects. The brain homogenates were frozen at 
-70°C until ready 3 f~r7 use. Frozen homogenates were placed 
directly into a water bath and incubated for 45 minutes to 
promote dissociation of endogenous llgands from the receptors. 
After centrifugation, the tissue was resuspended at a 
concentration of 50 mg tissue/m1 0.05 M t~is buffer. Aliquots 
o{ tissue (0.3ml) were incubated with [ H]-DADL enkephalin and 
[ H]-morphine at concentrations ranging from 0.5 nM to 25 nM in 
a total assay volume of 0.5 ml. One micromolar morphine and one 
micromolar DA~L enkephalln were used to define nonspecific 
binding for [ H]-morphine and ['H]-DADL enkephalln respectively. 
Because of the low ratio3of specific to nonspeclfi~ binding at 
high concentrations of [ H] ligand, a mixture of [ H] ligand and 
unlabelled llgand was used to calculate bound and free 
concentrations at higher concentrations of morphine and DADL 
enkephalin. In addition, samples were incubated with varying 
concentrations of unlabelled morphine w~th [ H]-DADL enkephalin 
and unlabelled DADL enkephalln wit9 [ H]-morphlne to determine 
IC~0 for both li~ands against both [ H] ligands. After a 2 hr, 
incubation at 4 C, samples were rapidly filtered under vacuum 
using Whatman GF/B glass fiber filters. The filters were washed 
twice with 4.5 ml of cold iris buffer, dispersed by shaking in 
i0 ml of Beckman aqueous scintillation cocktail and counted in a 
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Beckman LS9000 liquid scintillation counter. Biorad protein 
assays were used to determine that differences between MSG and 
control are not due to dilutional error. A given brain region 
for both MSG and control rats was completely studied in one 
experiment on one day. 
Dissociation constants (Kn) and receptor concentration 
(Bmax) were obtained from Sc~tchard plot analysis of the data 
for each ligand in each brain region using computer generated 
multiple linear regression analysis. 
RESULTS 
Immunohistochem ical analysis of brains from selected 
MSG-lesioned and control animals showed a consistent loss of 
B-END, immunolabelled in the arcuate of MSG-treated animals. 
The Scatchard analysis shows differences in only two brain 
regions, thalamus and striatum. Morphine and DADL enkephalin 
data show little if any change in the K_ between MSG treated and 
i) 
control groups. However, there are changes in the Bmax. In 
striatum, an increase in mu receptors (B control = 247pM; 
ax 
B MSG = 304 pM) was not accompanied ~y any changes in delta 
m x 
re@eptors. Due to the limited amount of striatal tissue 
available, we were unable to replicate this study. In thalamus, 
the number of delta receptors increased in the MSG lesioned rats 
(B control = 140 pM; B MSG = 244 pM) This increase could 
bem~en in the first group m~XMSG rats (9 months old) and was 
replicated in the 7 month old MSG rats. The cross-competition 
experiments further support this observation (Table i). 
Morphine, w~ich ordinarily is more potent in thalamus in 
displacing [~H] DADL than DADL enkephalin itself, lost much of 
its potency in the MSG group. The IC_ 0 of morphine changes from 
1.8 to 34nM. This loss of potency is consistent with an 
increase in delta receptors, such that the pattern of IC 
displacement is more characteristic of delta receptor-rlch are~ 
(e.g., striatum or cortex) than the mu receptor-rich thalamus. 
TABLE i. Thalamus 
IC50 (riM) in Cross Competition 
3H Morphine [3H] DADL 
Control MSG Control MSG 
Morphine* 1.3 i. 8 2.5 34 
DADL* 28 32 15 20 
*Mean of two experiments 
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DISCUSSION 
The use of multiple ligands and brain regional analysis is 
a sensitive and specific technique for detecting changes in 
opiate receptors. Most previous attempts to find opiate 
receptor changes have utilized whole brain and one ligand, 
generally morphine, dihydromorphine or etorphine. If opiate 
receptors exist in subtypes in vivo, the regulation of each 
subtype may be separate. Thus there is no reason to expect, a 
priori, that the use of only one ligand could demonstrate a 
selective change in one receptor subtype. In the case of the 
MSG lesion, the use of [~H]-DADL, a delta receptor ligand, was 
critical for the demonstration of the increase in B , since 
• • • m 
there were no changes in mu receptors. In addltlon ~e use of 
brain regional analysis was crucial since the change was 
confined to the thalamus, which is only 10% by weight of the 
whole brain. Since MSG lesions are confined to the brain B-END 
system, it is more appropriate to seek changes in specific 
terminal areas than in the whole brain. This report 
demonstrates an up regulation of opiate receptors in response to 
a chemical lesion destroying the arcuate nucleus B-END system. 
It is not known if this up-regulation represents a 
supersensitivity to delta-agonists in vivo. 
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